# US 2024/0252607 A1 · Immunotherapeutic molecules and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252607 A1
- Document ID: US20240252607A1
- Status: Published application
- Kind: A1
- Application number: 18/395,074
- Filed: 2023-12-22
- Published: 2024-08-01
- Earliest claimed: 2012-10-30
- Assignees: Aravax Pty Ltd
- Applicants: Aravax Pty Ltd
- Inventors: ROBYN O'HEHIR; JENNIFER ROLLAND; SARA PRICKETT
- Web page: https://patentgrep.com/patent/US20240252607A1

## CPC

- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/35: Allergens
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.

## Claims

### Claim 1

A vector comprising (i) one or more nucleic acid sequences encoding, or complementary to a nucleic acid sequence encoding, one or more peptides, each independently consisting of the amino acid sequence of any one of SEQ ID NOs: 1-10, 12-17, and 19-33, and (ii) one or more additional nucleic acid sequences, wherein the one or more nucleic acid sequences are ligated, fused or associated with the one or more additional nucleic acid sequences.

### Claim 2 (depends on 1)

The vector according to claim 1, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, one or more peptides, each independently consisting of the amino acid sequence of any one of:
(i)
(SEQ ID NO: 12)
FQNLQNHRIV
(ii)
(SEQ ID NO: 13)
RIVQIEAKPNTLV
(iii)
(SEQ ID NO: 14)
FQNLQNHRIVQIEAKPNTLV
(iv)
(SEQ ID NO: 15)
WSTRSSENNEGVIVKVSKE
(v)
(SEQ ID NO: 16)
STRSSENNEGVIVKVSKE
(vi)
(SEQ ID NO: 17)
ENNEGVIVKVSKE
(vii)
(SEQ ID NO: 19)
SNNFGKLFEVKPDKKNPQ
(viii)
(SEQ ID NO: 20)
EVKPDKKNPQLQ
(ix)
(SEQ ID NO: 21)
NNFGKLFEVKPDKKNPQLQ
(x)
(SEQ ID NO: 22)
SNNFGKLFEVKPDKKNPQLQ
(xi)
(SEQ ID NO: 24)
ALMLPHFNSKAMVIVVV
(xii)
(SEQ ID NO: 25)
KAMVIVVVNKG
(xiii)
(SEQ ID NO: 26)
AMVIVVVNKGTGNLELVAV
(xiv)
(SEQ ID NO: 27)
VVNKGTGNLELVAVRK
(xv)
(SEQ ID NO: 28)
AMVIVVVNKGTGNLELV
(xvi)
(SEQ ID NO: 29)
KAMVIVVVNKGTGNLELVAV
(xvii)
(SEQ ID NO: 30)
GDVFIMPAAHPVAINASS
(xviii)
(SEQ ID NO: 31)
VFIMPAAHPVAINASSE
(xix)
(SEQ ID NO: 32)
GDVFIMPAAHPVAINASSE
(xx)
(SEQ ID NO: 33)
VFIMPAAHPVAINASS.

### Claim 3 (depends on 2)

The vector according to claim 2, wherein at least one of the one or more nucleic acid sequence encodes, or is complementary to a nucleic acid sequence encoding, a peptide consisting of VEIKEGALMLPHFNSKA (SEQ ID NO: 23).

### Claim 4 (depends on 3)

The vector according to claim 3, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 23 together with one or more peptides defined by SEQ ID NOs: 12-17, 19-22 or 24-33.

### Claim 5 (depends on 3)

The vector according to claim 3, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 23 together with one or more peptides defined by SEQ ID NOs: 14, 16, 20, or 33.

### Claim 6 (depends on 3)

The vector according to claim 3, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 23 together with one or more peptides defined by SEQ ID NOs: 14, 20, or 33.

### Claim 7 (depends on 3)

The vector according to claim 3, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 23 together with peptides defined by SEQ ID NOs: 14, 20, and 33.

### Claim 8 (depends on 3)

The vector according to claim 3, wherein at least one of the one or more nucleic acid sequence encodes, or is complementary to a nucleic acid sequence encoding, a peptide consisting of FQNLQNHRIVQIEAKPNTLV (SEQ ID NO: 14).

### Claim 9 (depends on 3)

The vector according to claim 3, wherein at least one of the one or more nucleic acid sequence encodes, or is complementary to a nucleic acid sequence encoding, a peptide consisting of EVKPDKKNPQLQ (SEQ ID NO: 20).

### Claim 10 (depends on 3)

The vector according to claim 3, wherein at least one of the one or more nucleic acid sequence encodes, or is complementary to a nucleic acid sequence encoding, a peptide consisting of VFIMPAAHPVAINASS (SEQ ID NO: 33).

### Claim 11 (depends on 8)

The vector of claim 8, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 14 together with one or more peptides defined by SEQ ID NOs: 12-13, 15-17, or 19-33.

### Claim 12 (depends on 9)

The vector of claim 9, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 20 together with one or more peptides defined by SEQ ID NOs: 12-17, 19 or 21-33.

### Claim 13 (depends on 10)

The vector of claim 10, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 33 together with one or more peptides defined by SEQ ID NOs: 12-17, or 19-32.

### Claim 14 (depends on 8)

The vector according to claim 8, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 14 together with one or more peptides defined by SEQ ID NOs: 16, 20, 23, or 33.

### Claim 15 (depends on 9)

The vector according to claim 9, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 20 together with one or more peptides defined by SEQ ID NOs: 14, 16, 23, or 33.

### Claim 16 (depends on 10)

The vector according to claim 10, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 33 together with one or more peptides defined by SEQ ID NOs: 14, 16, 20, or 23.

### Claim 17 (depends on 8)

The vector according to claim 8, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 14 together with one or more peptides defined by SEQ ID NOs: 20, 23, or 33.

### Claim 18 (depends on 9)

The vector according to claim 9, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 20 together with one or more peptides defined by SEQ ID NOs: 14, 23, or 33.

### Claim 19 (depends on 10)

The vector according to claim 10, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, the peptide defined by SEQ ID NO: 33 together with one or more peptides defined by SEQ ID NOs: 14, 20, or 23.

### Claim 20 (depends on 1)

The vector according to claim 1, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, one or more peptides that are capable of reducing the severity of Ara h 1 hypersensitivity or sensitivity to an allergen present in a composition which comprises Ara h 1 when administered to a subject having a condition characterised by said hypersensitivity or sensitivity.

### Claim 21 (depends on 20)

The vector according to claim 20, wherein said condition is hypersensitivity to peanuts or tree nuts which contain Ara h 1.

### Claim 22 (depends on 20)

The vector according to claim 20, wherein said peptides are capable of desensitising or inducing immunological tolerance to Ara h 1.

### Claim 23 (depends on 22)

The vector according to claim 22, wherein said desensitization or tolerance is achieved by inducing Th2 anergy or apoptosis.

### Claim 24 (depends on 1)

The vector according to claim 1, wherein the one or more nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, one or more peptides that are capable of modifying T cell function when presented to T cells isolated from subjects having an Ara h 1 hypersensitivity or sensitivity to an allergen present in a composition which comprises Ara h 1.

### Claim 25 (depends on 1)

The vector according to claim 1, wherein the one or more additional nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, a signal peptide or a modulatory agent.

### Claim 26 (depends on 1)

The vector according to claim 1, wherein the vector is an expression vector.

### Claim 27 (depends on 1)

The vector according to claim 1, wherein the one or more additional nucleic acid sequences encode, or are complementary to a nucleic acid sequence encoding, a promoter, an enhancer, or a combination thereof.

### Claim 28 (depends on 1)

The vector according to claim 1, wherein the vector is functional in prokaryotic cells or eukaryotic cells.

### Claim 29 (depends on 1)

The vector according to claim 1, wherein the vector is a viral vector.
